-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) announced that the SAFFRON phase III study of combination therapy with ORPATHYS® (ORPATHYS®, savolitinib) and Teresa® (TAGRISSO®, osimertinib) compared with platinum dual-drug chemotherapy for patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer achieved positive top-line results, showing statistically and clinically significant progression-free survival (PFS) Save Period (OS) improvements. The tumors in the study were accompanied by high levels of MET overexpression or amplification, and the disease progressed after previous treatment with Teresa®.

Zhitongcaijing·08/17/2026 00:25:04
Listen to the news
Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) announced that the SAFFRON phase III study of combination therapy with ORPATHYS® (ORPATHYS®, savolitinib) and Teresa® (TAGRISSO®, osimertinib) compared with platinum dual-drug chemotherapy for patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer achieved positive top-line results, showing statistically and clinically significant progression-free survival (PFS) Save Period (OS) improvements. The tumors in the study were accompanied by high levels of MET overexpression or amplification, and the disease progressed after previous treatment with Teresa®.